Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Assembly Biosciences (ASMB) Total Non-Current Liabilities (2016 - 2018)

Historic Total Non-Current Liabilities for Assembly Biosciences (ASMB) over the last 4 years, with Q4 2018 value amounting to $38.9 million.

  • Assembly Biosciences' Total Non-Current Liabilities fell 883.54% to $38.9 million in Q4 2018 from the same period last year, while for Dec 2018 it was $38.9 million, marking a year-over-year decrease of 883.54%. This contributed to the annual value of $38.9 million for FY2018, which is 883.54% down from last year.
  • Per Assembly Biosciences' latest filing, its Total Non-Current Liabilities stood at $38.9 million for Q4 2018, which was down 883.54% from $38.9 million recorded in Q3 2018.
  • Assembly Biosciences' Total Non-Current Liabilities' 5-year high stood at $55.4 million during Q1 2017, with a 5-year trough of $11.1 million in Q4 2016.
  • Moreover, its 4-year median value for Total Non-Current Liabilities was $38.9 million (2018), whereas its average is $29.7 million.
  • Per our database at Business Quant, Assembly Biosciences' Total Non-Current Liabilities surged by 37792.58% in 2017 and then plummeted by 2648.54% in 2018.
  • Assembly Biosciences' Total Non-Current Liabilities (Quarter) stood at $11.6 million in 2015, then fell by 4.14% to $11.1 million in 2016, then surged by 283.93% to $42.7 million in 2017, then decreased by 8.84% to $38.9 million in 2018.
  • Its last three reported values are $38.9 million in Q4 2018, $38.9 million for Q3 2018, and $40.2 million during Q2 2018.